↓ Skip to main content

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

Overview of attention for article published in Clinical Epigenetics, May 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
3 X users
patent
2 patents

Citations

dimensions_citation
124 Dimensions

Readers on

mendeley
179 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Published in
Clinical Epigenetics, May 2017
DOI 10.1186/s13148-017-0358-y
Pubmed ID
Authors

Roberta Mazzone, Clemens Zwergel, Antonello Mai, Sergio Valente

Abstract

Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy. Indeed, modulating immune inhibitory pathways has been considered an important breakthrough in cancer treatment. Although immune checkpoint blockade therapy used to treat malignant diseases has provided promising results, both solid and haematological malignancies develop mechanisms that enable themselves to evade the host immune system. To overcome some major limitations and ensure safety in patients, recent strategies have shown that combining epigenetic modulators, such as inhibitors of histone deacetylases (HDACi) or DNA methyltransferases (DNMTi), with immunotherapeutics can be useful. Preclinical data generated using mouse models strongly support the feasibility and effectiveness of the proposed approaches. Indeed, co-treatment with pan- or class I-selective HDACi or DNMTi improved beneficial outcomes in both in vitro and in vivo studies. Based on the evidence of a pivotal role for HDACi and DNMTi in modulating various components belonging to the immune system, recent clinical trials have shown that both HDACi and DNMTi strongly augmented response to anti-PD-1 immunotherapy in different tumour types. This review describes the current strategies to increase immunotherapy responses, the effects of HDACi and DNMTi on immune modulation, and the advantages of combinatorial therapy over single-drug treatment.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 179 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Unknown 178 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 39 22%
Student > Ph. D. Student 32 18%
Student > Master 24 13%
Student > Bachelor 23 13%
Other 10 6%
Other 18 10%
Unknown 33 18%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 56 31%
Medicine and Dentistry 23 13%
Agricultural and Biological Sciences 22 12%
Pharmacology, Toxicology and Pharmaceutical Science 13 7%
Immunology and Microbiology 7 4%
Other 13 7%
Unknown 45 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2019.
All research outputs
#4,460,350
of 24,185,663 outputs
Outputs from Clinical Epigenetics
#316
of 1,356 outputs
Outputs of similar age
#74,971
of 319,830 outputs
Outputs of similar age from Clinical Epigenetics
#7
of 30 outputs
Altmetric has tracked 24,185,663 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,356 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,830 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.